Janux Therapeutics (JANX) announced the appointment of Janeen Doyle as chief corporate and business development officer. She joins Janux from Flagship Pioneering, a life sciences-focused venture capital firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Reports Increased Q1 Losses Amid R&D Expansion
- JANX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Janux Therapeutics price target lowered to $36 from $41 at Scotiabank
- Promising Pipeline and Strategic Advancements Justify Buy Rating for Janux Therapeutics Inc
- Positive Buy Rating for Janux Therapeutics Inc. Driven by Promising Clinical Data and Strong Financial Position